Aurobindo Pharma Ltd. Investor Presentation

Aurobindo Pharma Ltd. Investor Presentation: Get insights into company performance, financials, capex plans and more

announcement
Conference/Earnings Calls Alerts
1100.10
0.52%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated February 9, 2021 wherein we have intimated the schedule of Investors/ Analysts call on February 11, 2021. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter ended December 31, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/
1100.10
0.52%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated November 10, 2020 wherein we have intimated the schedule of Investors/ Analysts call on November 12, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second Quarter ended September 30, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated August 10, 2020 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first Quarter ended June 30, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated June 1, 2020 wherein we have intimated the schedule of Investors/ Analysts call on June 4, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth Quarter and year ended March 31, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated February 3, 2020 wherein we have intimated the schedule of Investors/ Analysts call on February 7, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2019. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
AUROBINDO PHARMA LTD. - 524804 - Investor / Analysts Presentation
BSE India
Please refer to our letter dated November 8, 2019 wherein we have intimated the schedule of Investors/ Analysts call on November 13, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second Quarter and half year ended September 30, 2019. The presentation is also being uploaded in the following weblink. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated August 5, 2019 wherein we have intimated the schedule of Investors/ Analysts call on August 8, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first Quarter ended June 30, 2019. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated May 24, 2019, wherein we have intimated the schedule of Investors/ Analysts call on May 29, 2019. In this connection, we enclose herewith the presentation on the Audited Financial Results of the Company for the financial year ended March 31, 2019. The presentation is also being uploaded on the website of the Company - https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated 5th February, 2019 wherein we have intimated the schedule of Investors/ Analysts call on February 8, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2018. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1100.10
0.52%
Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated 9th November, 2018 wherein we have intimated the schedule of Investors/Analysts call on 13th November, 2018. In this connection, we enclose herewith the presentation that would be used in the Investors/Analysts call on the Unaudited Financial Results of the Company for the second quarter and half year ended 30th September, 2018....